STOCK TITAN

TransCode Therapeutics Inc - RNAZ STOCK NEWS

Welcome to our dedicated news page for TransCode Therapeutics (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on TransCode Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TransCode Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TransCode Therapeutics's position in the market.

Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the publication of a US Patent Application focusing on innovative cancer therapy using RNA therapeutics. The application targets RIG-I-like receptors to activate the immune system against cancer cells, potentially revolutionizing cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has received notice from the Nasdaq Stock Market LLC that it has regained compliance with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing. The company will be subject to a mandatory panel monitor through January 26, 2025. Additionally, the company was notified that it was not in compliance with the minimum bid price rule, and it must regain compliance by May 6, 2024, or be eligible for an additional 180 calendar day compliance period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
-
Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces a co-research agreement with Debiopharm to explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer. The collaboration aims to test the development of new targeted nucleic acid delivery modalities, with the potential to revolutionize cancer research and treatment. TransCode's lead therapeutic candidate, TTX-MC138, designed to use antisense technology to treat metastatic cancer, is being evaluated in an early-stage clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
Rhea-AI Summary
TransCode Therapeutics, Inc. (RNAZ) has closed a public offering, raising $7.25 million in gross proceeds. The offering included 5,942,623 shares of common stock and warrants to purchase up to 11,885,246 shares at a price of $1.22 per share. The company plans to use the net proceeds for product development activities, including clinical trials with its lead therapeutic candidate, TTX-MC138, and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
offering
-
Rhea-AI Summary
TransCode Therapeutics, Inc. (RNAZ) announces the pricing of a public offering of 5,942,623 shares of common stock and warrants to purchase up to 11,885,246 shares at a combined public offering price of $1.22 per share. The warrants will have an exercise price of $1.22 per share and will expire three and one-half years from the date of issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.3%
Tags
offering
-
Rhea-AI Summary
TransCode Therapeutics, Inc. (RNAZ) reported further steps in its restructuring to reduce expenditures and focus on its lead therapeutic candidate. The CEO announced his retirement, and the CFO will become interim CEO. The Chief Technology Officer has been promoted to Chief Scientific Officer, and the Chairman of the Board of Directors will assume the position of Executive Chairman.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced a 1-for-40 reverse stock split to increase the per share trading price and satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse split will reduce the number of shares of outstanding common stock from approximately 25,097,596 shares to approximately 627,448 shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.57%
Tags
stock split
-
Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) raised $18.5M in capital despite difficult financial markets and initiated its first clinical trial for its lead therapeutic candidate, TTX-MC138, designed to treat metastatic disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.18%
Tags
none
-
Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) successfully completed a preclinical study on its lead therapeutic candidate, TTX-MC138, in pancreatic adenocarcinoma, demonstrating its effectiveness against metastatic pancreatic cancer in animal models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.57%
Tags
clinical trial
Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) will present data from a Phase 0 clinical trial with its lead candidate, TTX-MC138, at the San Antonio Breast Cancer Symposium. The trial involves injection of a microdose of Cu64-labeled TTX-MC138 into stage IV breast cancer patients, followed by PET-MRI to determine the pharmacokinetics of TTX-MC138 and its uptake in metastatic lesions. The company believes that these data show the potential for TTX-MC138 to accumulate in human metastases, support further clinical development, and enable clinical development of a wide array of TTX-based therapeutic candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.95%
Tags
conferences
TransCode Therapeutics Inc

Nasdaq:RNAZ

RNAZ Rankings

RNAZ Stock Data

760.59k
502.26k
1.35%
2.99%
20.91%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boston

About RNAZ

transcode therapeutics is a boston based pre-clinical biopharmaceutical company focused on discovery, development and commercialization of a pipeline of innovative microrna (mirnas or mirs) therapeutics for treating metastatic disease.